Daniel Kiiza

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 137 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Thokozile R. Malaba, Irene Nakatudde, Kenneth Kintu et al. · The Lancet HIV · 2022 · 53 citations · Full text

Public Health, Maternal Health, Pharmacotherapy +17

Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial

David S. Lawrence, Charles Muthoga, David B. Meya et al. · The Lancet Global Health · 2022 · 30 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda

Prosperity Eneh, Katherine Huppler Hullsiek, Daniel Kiiza et al. · BMC Infectious Diseases · 2020 · 17 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +12

Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study

Tshepiso Mbangiwa, Aude Sturny-Leclère, Kwana Lechiile et al. · The Lancet Microbe · 2024 · 16 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +17